https://www.med-cannabis2019.com/position-of-the-european-pain-federation-efic®-on.aspx
The quantity and quality of evidence are such that cannabis‐based medicines may be reasonably considered for chronic neuropathic pain. For all other chronic pain conditions (cancer, non‐neuropathic non-cancer pain), the use of cannabis‐based medicines should be regarded as an individual therapeutic trial.
Realistic goals of therapy have to be defined.
Leave a Reply